Aprea Therapeutics, Inc. (APRE) Free cash flow 2019–2025
Aprea Therapeutics, Inc. (APRE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$12.9MFY2025 · since FY2019: -$26.7M → -$12.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$12.9M | +5.4% |
| FY2024 | -$13.6M | — |
| FY2021 | -$37.7M | +9.9% |
| FY2020 | -$41.8M | -56.6% |
| FY2019 | -$26.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More APRE financial trends
APRE RevenueAPRE Net incomeAPRE Net marginAPRE Gross profitAPRE Gross marginAPRE Operating incomeAPRE Operating marginAPRE Operating cash flowAPRE Capital expendituresAPRE Return on equityAPRE Stock buybacksAPRE Dividends paidAPRE Total assetsAPRE Total liabilitiesAPRE Shareholders’ equityAPRE overview →